Quince Therapeutics to host virtual KOL event on PH-ILD, BOS treatment landscape and LAM-001
QNCX•Virtual KOL event to cover PH-ILD, BOS and LAM-001
Quince Therapeutics will host a virtual KOL event on Sept. 28, 2026, from 12:30-2:00 p.m. ET.
Discussion will cover treatment landscapes for PH-ILD and BOS, focusing on LAM-001, an inhaled rapamycin dry powder formulation in Phase 2 trials.
Presentations will include recently disclosed Phase 2a pulmonary hypertension data, plus updates on ongoing Phase 2 BOS and Phase 2b PH-ILD studies.
